MBS303 * Melestarikan Hutan Indonesia untuk Masa Depan yang

mbs303 MBS 303 is a bispecific antibody targeting CD3CD20 being developed by Beijing Mabworks Biotech for the treatment of B cell non-Hodgkin lymphoma. The. MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity

mbs303, The latest posts on #mbs303. Read what people are saying and join the conversation..